biostudies-otherUnknownhttps://www.ebi.ac.uk/biostudies/studies/S-DIXA-014PredToxbiostudies-otherfalseStudy FP004BA: Evaluation of the Acute Toxicity, Gene Expression, Protein Expression, Metabolite Production, Clinical Chemistry and Pathology Profile Following an Oral Administration of Compound Bay 16-4749 to RatsRepeated dose 14-day toxicity study in adult male rats (Rattus norvegicus), Wistar strain, using chemical compound FP004BA, administered daily orally, sponsored by Bayer Schering Pharma AG, funded by European Union Framework Program 6 - Innovative Medicines Initiatives - Integrated Project Predictive Toxicology (EU FP6 InnoMed PredTox: LSHB-CT-2005-518170), The study will examine the gene, protein and metabolite profiles, along with traditional toxicological endpoint information in the liver, kidney, blood and urine of rats 1-14 days after exposure. By design, low doses lie between No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL).2016-06-30T10:26:24Z2016-06-30T10:26:18Z2016-06-01T12:12:27ZS-DIXA-014